首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   16158篇
  免费   724篇
  国内免费   201篇
耳鼻咽喉   87篇
儿科学   166篇
妇产科学   71篇
基础医学   1101篇
口腔科学   182篇
临床医学   1549篇
内科学   1068篇
皮肤病学   116篇
神经病学   651篇
特种医学   421篇
外国民族医学   1篇
外科学   767篇
综合类   2911篇
预防医学   3281篇
眼科学   67篇
药学   3719篇
  12篇
中国医学   648篇
肿瘤学   265篇
  2023年   158篇
  2022年   296篇
  2021年   393篇
  2020年   398篇
  2019年   274篇
  2018年   306篇
  2017年   305篇
  2016年   272篇
  2015年   424篇
  2014年   1298篇
  2013年   1460篇
  2012年   1612篇
  2011年   1613篇
  2010年   1331篇
  2009年   1042篇
  2008年   916篇
  2007年   904篇
  2006年   685篇
  2005年   592篇
  2004年   408篇
  2003年   335篇
  2002年   255篇
  2001年   225篇
  2000年   204篇
  1999年   169篇
  1998年   143篇
  1997年   116篇
  1996年   110篇
  1995年   77篇
  1994年   78篇
  1993年   59篇
  1992年   58篇
  1991年   64篇
  1990年   41篇
  1989年   56篇
  1988年   45篇
  1987年   39篇
  1986年   38篇
  1985年   44篇
  1984年   32篇
  1983年   15篇
  1982年   21篇
  1980年   18篇
  1979年   18篇
  1978年   14篇
  1977年   14篇
  1974年   14篇
  1973年   23篇
  1971年   12篇
  1969年   11篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
一测多评法(quantitative analysis of multi-components by single marker,QAMS)已成熟应用于中药材、中药提取物及中成药领域等中药复杂体系的质量评价研究中,有效解决了因对照品缺乏而导致的多指标质控技术推广难问题。本文查阅近五年的国内外研究文献,重点总结了高效液相色谱、气相色谱和质谱等技术在QAMS法中药质量控制中的应用。高效液相色谱联用紫外检测器(UV)技术应用最为广泛,最适合于中药QAMS法定量,结果稳定、准确;而高效液相色谱联用蒸发光检测器在中药QAMS法应用中,其测定准确性和适用性仍然需进一步探索和验证。液质联用技术虽然具有灵敏度高、线性范围宽等优点,但易受仪器参数、基质效应等的影响。进一步发展HPLC-UV技术在中成药制剂质量评价中的应用,是QAMS法多成分定量值得关注的方向;探索LC-MS和GC技术在中药QAMS质量评价中的稳定性和普适性是未来将面临的挑战。  相似文献   
2.
吴鞠通著《温病条辨》倡三焦辨证,形成了以卫气营血、三焦为核心的温病辨证体系,其中卷六《解儿难》结合温病理论阐释了其对儿科疾病和治疗用药的独特见解。吴鞠通解小儿“纯阳”为“稚阳未充,稚阴未长”,其易于感邪、易于传变,治疗用药需谨慎。本文结合吴鞠通对小儿生理病理特点的认识,从谨慎选药、慎用苦寒、多甘少酸、巧用辛温、善用辛凉、重视脾胃、辅以食疗七个方面阐释吴鞠通儿科方面的用药特点,以期为儿科临床用药提供参考。  相似文献   
3.
《Indian heart journal》2022,74(4):302-306
BackgroundThe alarming rise in prevalence of hypertension warrants psychosocial methods supplementing pharmacotherapy for better management and prevention of cardiac emergencies. The objective of the study was to assess the differential impact of the form and frequency of knowledge intervention on management of primary hypertension.Materials and methodThe study was conducted on 256 hypertensive patients recruited through purposive sampling at health centers in Hyderabad, India. Pretest post-test control group quasi-experimental design was adopted for the study. There were two forms of the knowledge intervention, namely ‘Direct Interaction’ and ‘Audio-Visual’. Each form was presented in two frequencies namely ‘single exposure’ and ‘double exposure’. The four groups were labelled as Direct Intervention Single (DIS), Direct Intervention Double (DID), Audio-Visual Single (AVS) and Audio-Visual Double (AVD). Adherence and management of hypertension were assessed at baseline and six weeks post experiment. Analysis of Covariance (ANCOVA) was applied using IBM SPSS Statistics version 20.ResultsANCOVA followed by Bonferroni Multiple Group Comparison Test revealed significant differences between the four intervention groups and control group on adherence (p< .001). In case of hypertension management significant differences were observed between Control group and DIS, DID (p < .001), Control and AVS (p < .01). Control group did not differ from AVD.ConclusionThere was a positive impact of Knowledge Intervention on adherence and management of hypertension. Double exposure in audio visual form was counterproductive in hypertension management.  相似文献   
4.
IntroductionMounting evidence supports a role for estrogen signaling in NSCLC progression. We previously reported a seven-gene signature that predicts prognosis in estrogen receptor β positive (ERβ+) NSCLC. The signature defines a network comprised of ER and human EGFR-2/3 (HER2/HER3) signaling.MethodsWe tested the efficacy of combining the pan-HER inhibitor, dacomitinib, with the estrogen antagonist, fulvestrant, in ERβ+ NSCLC models with differing genotypes. We assessed the potency of this combination on xenograft growth and survival of host mice, and the ability to reverse the gene signature associated with poor outcome.ResultsSynergy was observed between dacomitinib and fulvestrant in three human ERβ+ NSCLC models: 201T (wild-type EGFR), A549 (KRAS mutant), and HCC827 (EGFR 19 deletion) with combination indices of 0.1-0.6. The combination, but not single agents, completely reversed the gene signature associated with poor prognosis in a mechanism that is largely mediated by activator protein 1 downregulation. In vivo, the combination also induced tumor regression and reversed the gene signature. In HCC827 xenografts treated with the combination, survival of mice was prolonged after therapy discontinuation, tumors that recurred were less aggressive, and two mechanisms of HER inhibitor resistance involving c-Met activation and PTEN loss were blocked.ConclusionsThe combination of an ER blocker and a pan-HER inhibitor provides synergistic efficacy in different models of ERβ+ NSCLC. Our data support the use of this combination clinically, considering its ability to induce potent antitumor effects and produce a gene signature that predicts better clinical outcomes.  相似文献   
5.
Benign breast disease (BBD) is an established breast cancer (BC) risk factor, but it is unclear whether the magnitude of the association applies to women at familial or genetic risk. This information is needed to improve BC risk assessment in clinical settings. Using the Prospective Family Study Cohort, we used Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the association of BBD with BC risk. We also examined whether the association with BBD differed by underlying familial risk profile (FRP), calculated using absolute risk estimates from the Breast Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) model. During 176,756 person-years of follow-up (median: 10.9 years, maximum: 23.7) of 17,154 women unaffected with BC at baseline, we observed 968 incident cases of BC. A total of 4,704 (27%) women reported a history of BBD diagnosis at baseline. A history of BBD was associated with a greater risk of BC: HR = 1.31 (95% CI: 1.14–1.50), and did not differ by underlying FRP, with HRs of 1.35 (95% CI: 1.11–1.65), 1.26 (95% CI: 1.00–1.60), and 1.40 (95% CI: 1.01–1.93), for categories of full-lifetime BOADICEA score <20%, 20 to <35%, ≥35%, respectively. There was no difference in the association for women with BRCA1 mutations (HR: 1.64; 95% CI: 1.04–2.58), women with BRCA2 mutations (HR: 1.34; 95% CI: 0.78–2.3) or for women without a known BRCA1 or BRCA2 mutation (HR: 1.31; 95% CI: 1.13–1.53) (pinteraction = 0.95). Women with a history of BBD have an increased risk of BC that is independent of, and multiplies, their underlying familial and genetic risk.  相似文献   
6.
目的:研讨急性心肌梗死患者行优化急诊护理流程的临床效果。方法:摘取单县中医医院2017年8月-2018年11月接收的110例急性心肌梗死患者资料,55例行优化急诊护理流程(研究组),55例行常规护理流程(对照组),比对两组临床指标与心理状态。结果:研究组接诊、术后转运、抢救准备及分诊台停留所用的时间(8.30±2.01)min、(14.67±2.53)min、(7.43±1.19)min、(2.01±0.44)min比对照组短,且抑郁自评量表(Self-rating Depression Scale,SDS)与焦虑自评量表(Self-Rating Anxiety Scale,SAS)评分(40.03±2.36)分、(41.75±1.18)分比对照组低(P<0.05),差异有统计学意义。结论:在抢救中给予急性心肌梗死患者优化急诊护理流程能改善其负面情绪,缩短接诊、术后转运、抢救准备等所用的时间。  相似文献   
7.
Background: Making progressin treatment of all branches of cancers has increasedthe percent of patients that never experience the event of interest. These cases are called immune or cure and models for handling the data included cure fraction rate, are referred to as cure model or long-term survival models. Methods:The data for this historical cohort study, were collected from leukemia patients diagnosed between 2007 to 2014 and followed up until 2016 in Taleghani hospital and received BMT (Bone Marrow Transplant). Some data had to be excluded because of incomplete information. Using recorded files mostly and phone calls rarely, were made to confirm whether the patients were still alive or not. Death due to leukemia was regarded as interested event. Analysis were performed by R version 3.4.1and Stata version 14. Results: Number of recurrents after receiving BMT, pre-transplant Hb and age at diagnosis were found as significant prognostics of survival time. HD patients had the highest 5-years overall survival in category of diagnosis type with 81.3%. Cure fraction was estimated to be 64.1%. Conclusion: According to high percentage of censoring, using long-term model had better fit.  相似文献   
8.
9.
《Clinical neurophysiology》2019,130(9):1465-1473
ObjectiveTo assess the feasibility of motor unit number index (MUNIX) in the quantitative assessment of the cervical spondylotic amyotrophy (CSA).MethodsMUNIX was recorded bilaterally on the abductor pollicis brevis, abductor digiti minimi, biceps brachii and middle deltoid in 41 normal controls and 47 patients with CSA (distal-type to proximal-type ratio: 25 to 22). Additionally, patients were assessed on handgrip strength (HGS), the disabilities of arm, shoulder and hand (DASH) and Medical Research Council (MRC) scales. These examinations were re-evaluated approximately 18 months after surgery in 37 of these CSA patients.ResultsMUNIX values were noticeably lower in the mainly affected muscles of CSA patients than those in controls (P < 0.05), and 49.0% (51/104) of the tested muscles with abnormal MUNIX measurements showed normal muscle strength. Significant correlations between MUNIX measurements and both DASH and MRC scores were observed in both CSA patient groups (P < 0.05). Postoperative longitudinal follow-up analysis identified significant increase in motor unit number in both CSA patient groups within approximately 18 months (P < 0.05), with or without improved measures of motor function.ConclusionsA significant reduction in MUNIX values related to motor impairment was observed in CSA patients, even in the subclinical stage. Compared to measures of motor function, the MUNIX measurements in the patients with CSA improved more noticeably after surgical intervention.SignificanceMUNIX may serve as an available supplementary test to quantitatively evaluate the motor dysfunction in CSA and to track its progression, that is complementary to conventional electromyography.  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号